The raised guidance and projection of double-digit growth in 2027 signal sustained momentum. Watch for the January 2027 detailed guidance and any M&A announcements that could accelerate growth beyond organic trends.
Drugs in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
Price Chart
Executive Summary
Kamada reported record Q3 2026 revenue of $52.0M (up 11% YoY) and net income of $8.0M ($0.14/diluted share, up 51% YoY). The company raised its 2026 full-year guidance to $205M-$208M in revenue and $52M-$54M in adjusted EBITDA, projecting double-digit growth into 2027.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $52.0M, up 11% from $47.0M in Q3 2025
- Q3 2026 net income $8.0M ($0.14/diluted share), up 51% from $5.3M ($0.09/diluted share)
- Q3 2026 adjusted EBITDA $15.2M (29% margin), up 30% from $11.7M
- Nine-month 2026 revenue record $152.2M, up 12% YoY
- Nine-month 2026 adjusted EBITDA record $40.9M (27% margin), up 20% YoY
- 2026 guidance raised: revenue $205M-$208M (prior $200M-$205M), adjusted EBITDA $52M-$54M (prior $50M-$53M)
- Cash dividend of $0.14/share declared (~$8.0M), total 2026 dividends $0.56/share (~$32.2M)
- Operating cash flow $37.6M in first nine months 2026, up from $17.9M in 2025
- Cash balance $75.3M at September 30, 2026
Financial Impact
Revenue guidance raised to $205M-$208M (midpoint 14% YoY growth); adjusted EBITDA guidance raised to $52M-$54M (midpoint 26% YoY growth)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Proprietary Products | $44.2M | +11.8% |
| Distribution | $7.8M | +4.8% |
Risk Factors
- Counterclaim in arbitration increased to $15.5M from $6.7M, outcome uncertain
- Geopolitical risks in Israel and Middle East conflicts
- Potential tariff impacts on international trade and profit levels
- Dependence on KEDRAB demand and CDC health advisory dynamics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-117189 |
| Document: ea031017901ex99-2.htm | 0001213900-26-117189 |
| Document: ea0310179-6k_kamada.htm | 0001213900-26-117189 |
| Document: ea031017901ex99-3.htm | 0001213900-26-117189 |
| Document: ea031017901ex99-1.htm | 0001213900-26-117189 |
| Document: 0001213900-26-117189-index-headers.html | 0001213900-26-117189 |
| Document: 0001213900-26-117189-index.html | 0001213900-26-117189 |
| Document: 0001213900-26-117189.txt | 0001213900-26-117189 |
| Earnings Context (Synthetic; results releases only) | 0001213900-26-117189 |
Track record
25 reports on KMDA
8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Viewing No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers